CRKL is altered in 0.91% of malignant solid tumor patients with CRKL Mutation present in 0.32% of all malignant solid tumor patients [4].

CRKL Mutation is an inclusion criterion in 24 clinical trials for malignant solid tumor, of which 20 are open and 4 are closed. Of the trials that contain CRKL Mutation and malignant solid tumor as inclusion criteria, 13 are phase 1 (11 open), 4 are phase 1/phase 2 (4 open), and 7 are phase 2 (5 open) [5].

CRKL is altered in 0.9% of non-small cell lung carcinoma patients with CRKL Mutation present in 0.25% of all non-small cell lung carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 7 are open and 1 is closed. Of the trials that contain CRKL Mutation and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].

CRKL is altered in 0.51% of breast carcinoma patients with CRKL Mutation present in 0.14% of all breast carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 6 are open and 0 are closed. Of the trials that contain CRKL Mutation and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [5].

CRKL is altered in 2.81% of melanoma patients with CRKL Mutation present in 0.71% of all melanoma patients [4].

CRKL Mutation is an inclusion criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain CRKL Mutation and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [5].

CRKL is altered in 0.2% of non-hodgkin lymphoma patients with CRKL Mutation present in 0.13% of all non-hodgkin lymphoma patients [4].

CRKL Mutation is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 4 are open and 1 is closed. Of the trials that contain CRKL Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (3 open) [5].

CRKL is altered in 0.77% of colorectal carcinoma patients with CRKL Mutation present in 0.48% of all colorectal carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain CRKL Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

CRKL Mutation is an inclusion criterion in 3 clinical trials for histiocytic and dendritic cell neoplasm, of which 2 are open and 1 is closed. Of the trials that contain CRKL Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 3 are phase 2 (2 open) [5].

CRKL is altered in 1.46% of ovarian carcinoma patients with CRKL Mutation present in 0.4% of all ovarian carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 1.17% of head and neck squamous cell carcinoma patients with CRKL Mutation present in 0.39% of all head and neck squamous cell carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CRKL Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

CRKL is altered in 0.5% of glioma patients with CRKL Mutation present in 0.32% of all glioma patients [4].

CRKL Mutation is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain CRKL Mutation and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

CRKL is altered in 0.57% of hepatocellular carcinoma patients with CRKL Mutation present in 0.28% of all hepatocellular carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

CRKL is altered in 1.3% of squamous cell lung carcinoma patients with CRKL Mutation present in 0.22% of all squamous cell lung carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 0.44% of thyroid gland carcinoma patients with CRKL Mutation present in 0.17% of all thyroid gland carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

CRKL is altered in 0.23% of low grade glioma patients with CRKL Mutation present in 0.11% of all low grade glioma patients [4].

CRKL Mutation is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain CRKL Mutation and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain CRKL Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

CRKL is altered in 0.29% of renal cell carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL Mutation and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

CRKL is altered in 1.46% of endometrial carcinoma patients with CRKL Mutation present in 1.2% of all endometrial carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 1.8% of thyroid gland undifferentiated (anaplastic) carcinoma patients with CRKL Mutation present in 0.9% of all thyroid gland undifferentiated (anaplastic) carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CRKL is altered in 3.0% of cutaneous melanoma patients with CRKL Mutation present in 0.88% of all cutaneous melanoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 1.31% of urothelial carcinoma patients with CRKL Mutation present in 0.57% of all urothelial carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 0.48% of multiple myeloma patients with CRKL Mutation present in 0.48% of all multiple myeloma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 0.59% of astrocytic tumor patients with CRKL Mutation present in 0.39% of all astrocytic tumor patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 0.54% of diffuse glioma patients with CRKL Mutation present in 0.34% of all diffuse glioma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 0.86% of cancer patients with CRKL Mutation present in 0.3% of all cancer patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and cancer as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 0.64% of gastric adenocarcinoma patients with CRKL Mutation present in 0.26% of all gastric adenocarcinoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CRKL Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

CRKL is altered in 0.3% of hematologic and lymphocytic disorder patients with CRKL Mutation present in 0.23% of all hematologic and lymphocytic disorder patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 0.17% of hematopoietic and lymphoid system neoplasm patients with CRKL Mutation present in 0.13% of all hematopoietic and lymphoid system neoplasm patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 0.35% of prostate carcinoma patients with CRKL Mutation present in 0.13% of all prostate carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

CRKL is altered in 0.15% of hematopoietic and lymphoid malignancy patients with CRKL Mutation present in 0.11% of all hematopoietic and lymphoid malignancy patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 0.36% of pancreatic carcinoma patients with CRKL Mutation present in 0.11% of all pancreatic carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 1.3% of soft tissue sarcoma patients with CRKL Mutation present in 0.1% of all soft tissue sarcoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 0.09% of acute myeloid leukemia patients with CRKL Mutation present in 0.09% of all acute myeloid leukemia patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

CRKL is altered in 0.04% of myeloid neoplasm patients with CRKL Mutation present in 0.04% of all myeloid neoplasm patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 0.93% of chondrosarcoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 2.99% of embryonal rhabdomyosarcoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 0.69% of Ewing sarcoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 1.16% of liposarcoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 1.18% of malignant peripheral nerve sheath tumor patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 0.27% of neuroblastoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 0.84% of osteosarcoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 1.19% of peritoneal mesothelioma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 0.65% of poorly differentiated thyroid gland carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL is altered in 1.12% of small cell lung carcinoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CRKL Mutation is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [5].

CRKL is altered in 1.4% of undifferentiated pleomorphic sarcoma patients [4].

CRKL Mutation is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL Mutation and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].